InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Berkenblit Anna, Vice-Présidente Senior et Directrice Médicale. Officer active across 1 company, notably ImmunoGen, Inc.. Aggregated, 5 reports have been logged. Activity tracked since 30 June 2021. The latest transaction was filed on 30 June 2023 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Berkenblit Anna
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
3,264 shares@ US$4.0519.7% of flowCommon StockSEC:0001415889-23-010828:0
436 shares@ US$3.922.6% of flowCommon StockSEC:0001415889-23-000108:0
3,073 shares@ US$3.82518.2% of flowCommon StockSEC:0001415889-22-007332:0
1,761 shares@ US$5.6020.1% of flowCommon StockSEC:0001179110-22-000106:0
2,062 shares@ US$5.5222.2% of flowCommon StockSEC:0001179110-21-007318:0
5 of 5 declarations
About Berkenblit Anna
Anna Berkenblit is the Senior Vice President and Chief Medical Officer at ImmunoGen, Inc. She oversees the medical and scientific activities of the company, ensuring alignment with strategic objectives. Her expertise is crucial for the development of new treatments.
